the harsh reaction conditions,5 the use of substituted alkynes
is rare and gives regioisomeric mixtures of products in low
yields (Scheme 1).6 These limitations are regrettable given
tion and the conversion of the O-vinyl oxime products to
pyrroles with mild heating (Scheme 1). The overall method
provides a simple, selective, and functional group tolerant
synthesis of 2,4- and 2,3,4-substituted pyrroles in two or three
steps from ketones and allyl hydroxylamine.
Alkene isomerization conditions for the conversion of
O-allyl oximes to O-vinyl oximes were screened for allyl
oxime 1a. This substrate was synthesized by a condensation
reaction between 4′-methoxyacetophenone and commericially
available, allyl hydroxylamine. Initially, known allylic ether
isomerization catalysts, such as [(Ph3P)3RhCl]/n-BuLi and
[(coe)2IrCl]2/PCy3/AgPF6, were tested and shown to be
ineffective for the desired transformation.9,10 Instead, a 1:2:2
mixture of [(cod)IrCl]2, NaBH4, and AgOTf successfully
catalyzed the conversion of 1a to 2a at 25 °C (Table 1, entries
Scheme 1. O-Vinyl Oximes as Precursors to Pyrroles
Table 1. Optimization of the O-Allyl Oxime Isomerization
Catalyst
entry
catalyst
yield (%)a
a Representative example.
1
2
3
4
5
6
7
(Ph3P)3RhCl/n-BuLi
NR
NRb
85
53
30
[(coe)2IrCl]2/2PCy3/2AgPF6
[(cod)IrCl]2/2NaBH4/2AgOTf
[(coe)2IrCl]2/2NaBH4/2AgOTf
(cod)2Rh(BF4)/NaBH4/AgOTf
[(coe)2RhCl]2/2NaBH4/2AgOTf
[(cod)IrCl]2/2LiAlH4/2AgOTf
the importance of substituted pyrrole architectures in me-
dicinal and material target molecules.7,8 To broaden the range
of pyrroles accessible from the [3,3] sigmatropic rearrange-
ment of O-vinyl oximes under more tolerant and efficient
conditions, we have developed an alkene isomerization
method to access O-vinyl oximes from easily prepared
O-allyl oximes. Here we report the scope of this isomeriza-
NR
89
a Determined by using 1H NMR spectroscopy with CH2Br2 as a
reference. b The reaction was done in THF and in 50:1 DCE:acetone.
1-3). Other common Ir(I) and Rh(I) catalyst precursors were
screened under the isomerization conditions but were less
efficient than [(cod)IrCl]2 (Table 1, entries 3-6). The
addition of phosphine ligands to the catalyst mixture and
the removal of AgOTf also inhibited the reaction. Several
reducing agents were screened and LiAlH4 and NaBH4 were
found to give the highest yields of 2a (Table 1, entries 3
and 7). A 2:1 ratio of the reducing reagent to the iridium
dimer was required because larger concentrations of the
reducing reagent provided small amounts of a side product
produced by reduction of the allyl group to an n-propyl
group.11 THF and MeCN were determined to be optimal
solvents for the isomerization. A significant decrease in yield
(5) For examples of the Trofimov reaction with acetylene, see: (a)
Mikhaleva, A. I.; Trofimov, B. A.; Vasil’ev, A. N. Zh. Org. Khim. 1979,
15, 602. (b) Korostova, S. E.; Mikhaleva, A. I.; Vasil’tsov, A. M.; Trofimov,
B. A. Russ. J. Org. Chem. 1998, 34, 911. (c) Trofimov, B. A.; Zaitsev,
A. B.; Schmidt, E. Y.; Vasil’tsov, A. M.; Mikhaleva, A. I.; Ushakov, I. A.;
Vashchenko, A. V.; Zorina, N. V. Tetrahedron Lett. 2004, 45, 3789. (d)
Trofimov, B. A.; Schmidt, E. Y.; Zorina, N. V.; Senotrusova, E. Y.; Protsuk,
N. I.; Ushakov, I. A.; Mikhaleva, A. I.; Meallet-Renault, R.; Clavier, G.
Tetrahedron Lett. 2008, 49, 4362. (e) Schmidt, E. Y.; Mikhaleva, A. I.;
Vasil’tsov, A. M.; Zaitsev, A. B.; Zorina, N. V. ARKIVOC 2005, 7, 11.
(6) For examples of regioisomeric mixtures of products obtained from
the use of terminal alkynes in the Trofimov reaction see: (a) Petrova, O. V.;
Sobenina, L. N.; Ushakov, I. A.; Mikhaleva, A. I.; Hyun, S. H.; Trofimov,
B. A. ARKIVOC 2009, 4, 14. (b) Trofimov, B. A.; Tarasova, O. A.;
Mikhaleva, A. I.; Kalinina, N. A.; Sinegovskya, L. M.; Henkelmann, J.
Synthesis 2000, 1585.
(7) For examples of the biological activity and medicinal application of
pyrroles, see: (a) Dewick, P. M. Medicinal Natural Products: A Biosynthetic
Approach; John Wiley& Sons Inc.: Chichester, UK, 2009. (b) Barton,
D. H. R.; Nakanishi, K.; MethCohn, O.; Kelly, J. W. ComprehensiVe Natural
Products Chemistry; Pergamon Press: Oxford, UK, 1999. (c) Cacchi, S.;
Fabrizi, G. Chem. ReV. 2005, 105, 2873. (d) Maryanoff, B. E.; Zhang, H.;
Cohen, J. H.; Turchi, I. J.; Maryanoff, C. A. Chem. ReV. 2004, 104, 1431.
(e) Saracoglu, N. Top. Heterocycl. Chem. 2007, 11, 1. (f) Zomax: McLeod,
D. C. Drug Intell. Clin. Pharm. 1981, 15, 522. (g) Atorvastin (Lipitor):
Roth, B. D. US4681893, 1987. (h) Muchowski, J. M. AdV. Med. Chem.
(9) For related syntheses of allyl vinyl ethers which undergo subsequent
Claisen rearrangements, see: (a) Wang, K.; Bungard, C. J.; Nelson, S. G.
Org. Lett. 2007, 9, 2325. (b) Nelson, S. G.; Bungard, C. J.; Wang, K. J. Am.
Chem. Soc. 2003, 125, 13000. (c) Schmidt, B. Synlett 2004, 9, 1541. (d)
Tanaka, K.; Okazaki, E.; Shibata, Y. J. Am. Chem. Soc. 2009, 131, 10822,
and references cited within
.
(10) For examples of allylic ether isomerizations see: (a) Tanaka, K.
Compr. Organomet. Chem. III 2007, 10, 71. (b) Corey, E. J.; Suggs, J. W.
J. Org. Chem. 1973, 38, 3224. (c) Boons, G.-J.; Isles, S. J. Org. Chem.
1992, 4, 181
.
(8) For examples of pyrrole structures in material applications see: (a)
Tshibaka, T.; Ulliel Roche, I.; Dufresne, S.; Lubell, W. D.; Skene, W. G.
J. Org. Chem. 2009, 74, 9497. (b) Walczak, R. M.; Reynolds, J. R. AdV.
1996, 61, 4262
.
(11) See the Supporting Information for full characterization of the O-n-
Mater. 2006, 18, 1121
.
propyl oxime reduction product.
Org. Lett., Vol. 12, No. 10, 2010
2291